Wednesday, February 10, 2010, 12:28PM AEST - The Australian Stockmarket closes in 3 hours and 37 minutes.
To create a watchlist or portfolio of shares, Register

ChemGenex Pharmaceuticals Ltd (CXS.AX)

12:01PM AEST: 0.720 AUD  Up 0.040 (5.88%)  
 MORE ON CXS.AX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Ownership
Financials
 CHEMGENEX FPO (ASX:CXS.AX) Delayed quote dataEdit
Last Trade:0.720 AUD
Trade Time:12:01PM AEST
Change:Up 0.040 (5.88%)
Prev Close:0.680
Open:0.700
Bid:0.715
Ask:0.725
1y Target Est:N/A
Day's Range:0.680 - 0.725
52wk Range:0.280 - 1.090
Volume:1,215,798
Avg Vol (3m):735,684
Market Cap:N/A
P/E (ttm):N/A
EPS (ttm):N/A
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add CXS.AX to Portfolio   Download Data

 HEADLINES 
•Australia shares fall 1.1 pct; banks down
Reuters Finance Australia (Tue 12:41PM)
•Extreme Weather in Washington D.C. has Postponed the FDAs Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010
Business Wire (Tue 12:01PM)
•Extreme Weather in Washington D.C. has Postponed the FDA's Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010
Business Wire (Tue 12:01PM)
•UPDATE - U.S. FDA staff questions small ChemGenex study
at Reuters (Tue 11:57AM)
•UPDATE - U.S. FDA staff questions small ChemGenex study
at Reuters (Tue 1:25AM)
•ChemGenex Pharmaceuticals Announces Omapro to be Reviewed by the FDAs Oncologic Drugs Advisory Committee for the Treatment of Adults with Chronic Myel
Business Wire (Thu, Dec 17)
•ChemGenex Pharmaceuticals Announces Omapro to be Reviewed by the FDA's Oncologic Drugs Advisory Committee for the Treatment of Adults with Chronic Myeloid Leukemia who have Failed Prior Therapy with Imatinib and have the Bcr-Abl T315I Mutat
Business Wire (Thu, Dec 17)
•ChemGenex, Hospira, Announce Agreement to License, Develop and Commercialize Leukemia Drug in Europe
Business Wire (Mon, Dec 14)
•ChemGenex, Hospira, Announce Agreement to License, Develop and Commercialize Leukemia Drug in Europe
Business Wire (Mon, Dec 14)
•ChemGenexs Omapro Featured During ASH Oral Session
Business Wire (Wed, Dec 9)
More Headlines for CXS.AX...
 BUSINESS SUMMARY 
ChemGenex Pharmaceuticals Limited (CXS) is a pharmaceutical development company with primary focus on the development of personalised oncology medicines. CXS has two molecules in clinical trials in the U.S. and a pipeline of pre-clinical anti-cancer compounds in development. CXS' lead compound for leukaemia is likely to reach market in 2009/2010.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices